Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This was an open-label, single dose parallel group study to evaluate the PK of iptacopan in participants with mild, moderate, and severe hepatic impairment compared to matched healthy control participants.
Epistemonikos ID: ff5de9b37490f689356ea055e7224a0ca07a1b45
First added on: May 09, 2024